Member Info for Laura2022

Falcon

In a fair world heat should SYNT be valued at today and us it worth buying to take up the rights issue?

Using 400% profits from POS and 100% RST I've added at 1.97p amd intended to add substantial more here and FCS

Good luck buying at 1.9p or in fact when news lands

Think by Friday you'll be glad you added more

I have

Clearly you haven't read it properly

In a nutshell they use mathematical modelling and A.I to see how drugs in use and drugs in development will be effective in treating certain cancers, they have a range of over 70 clients and have proven track record in getting drugs through the various development phases which hitherto have been hit and miss wjrh average drug to marker taking 10 years and 90%failure rate with wasted spend of $$mlns

Q: What competitive advantage does Physiomics have?

That’s a great question. We have several. On the one hand, we are a specialist in oncology mathematical modelling, and there are few companies out there that can say that with their hand on heart.  We have competitors that do mathematical modelling who tend to be generalists.  We have competitors that focus on oncology, but they don’t tend to be specialists in modelling.  So I believe the confluence of those two things is a position where we have a unique market opportunity.  The second thing I would say is our people and our experience are really second to none.  They work hard, they’re smart and they’re universally well respected by the clients that we take on.  I also believe that we’re making genuinely important contributions to the R&D efforts of the clients that that we work with, and that has led to a significant boost in our reputation.

When I arrived at the Company 5-6 years ago, we were fairly little known other than amongst a small circle of clients that we’d been working with for a while.  Now we’re getting referrals; people that we work with, talk to their friends and literally relatives sometimes, and we get phone calls from those individuals who may be working in in other companies. We’ve had several projects commissioned in this way, and this is extremely gratifying.   I think it’s a real demonstration that what we do makes a difference and that our clients continue to value that.

· ranging from 70p to 125p

as to 81,840 New Options (representing 33% of the total Options), provided that the average share price of the Company exceeds 75 pence (50% share price growth over the Exercise Price) for a period of 10 business days;

· as to 81,840 New Options (representing 33% of the total Options), provided that the average share price of the Company exceeds 100 pence (100% share price growth over the Exercise Price) for a period of 10 business days; and

· as to the balance of 84,320 New Options (representing 34% of the total Options), provided that the average share price of the Company exceeds 125 pence (150% growth over the Exercise Price) for a period of 10 business days.

Once vested the New Options are exercisable between 1 January 2023 and 21 December 2032, subject to accelerated vesting and exercise in certain customary scenarios.

It will be good to see it when those who have turned on q sixpence or gone quiet realise the big rise is only just starting

£3mln market cap /2.4p is so incredibly undervalued

I was in POS from 3p ,it did go to 17p in a straight line,I staged up and each mew stage took it higher

It will be great went news lands and PYC goes to the best higher level

Strange posts and contributions from some people today, some who have gone full circle

Very odd

Amica

Best just looking back through the posts over the last few weeks amd also the kast 3mths of RNSs

I will try to do a simple summary tonight

Purchased £2000 more from profits at RST ,will add another £10,000 this week

I've now seen another share of mine (RST) do 100% in one month to add to MIRI POS PYC

FCS is next to re rate

Great news ..now nearly 100%up on my summer purchases

As Stephen has said ,day to day worries about x or y price are irrelevant to where PYC is heading ...

FCS next

Amati huge seller out 3mths ago

Tr1 buyers in (see RNSs Last 2mths)

5mln shares issue and only £1.3 cap with £1.9mlnncash as of Sept 2022 and net assets £3mln

Cyber security growth expected

October - Dec 2022 Sales up 44% and same period 2021

, we have several large-scale opportunities advancing with major global technology providers (both new and existing relationships) to partner as part of their Cyber go-to-market plans. As ever these opportunities could be transformational for Falanx

Results for year ended March 2023 published Sept 2023

Please could we keep this board argument free ?

April 2023

o  Further development of our dosing tool for use in guiding the use of granulocyte/ macrophage colony stimulating factor (GCSF) - as outlined in our update on 9 January 2023. We see significant potential in the adaptation of our current personalised dosing tool to support clinical decision making on the use of this expensive biological drug and indeed the concept has received early positive feedback when tested with a small number of US clinicians. The Company is actively exploring non-dilutional grant funding opportunities for all its personalised dosing initiatives and if successful these could provide additional sources of funding in FY24

o  Collaboration with DoseMe - the Company is in an ongoing dialogue with the new management of DoseMe and further announcements on this will be made in due course

Well worth a read,this was published in relation tk the new FDA guidelines called 'Project Optimus " and was from the PYC RNS in April 2023

Here is the first paragraphs

Should personalised dosing have a role in cancer treatment?

Claire C. Villette David Orrell Jim Millen Christophe Chassagnole*

Physiomics PLC, Oxford, United Kingdom

Almost all pharmaceutical products are approved on the basis of their effect in patients representing the “average” of the population studied in registrational trials, with most drug labels allowing, at most, for empirical dose reduction in the case of toxicity. In this perspective article we explore some of the evidence that supports the use of personalised dosing in cancer treatment and show how we have been able to build on existing models linking dose, exposure and toxicity to demonstrate how dose optimisation, including increasing the dose, has the potential to significantly improve efficacy outcomes. We also explore, through the lens of our own experience of developing a personalised dosing platform, some of the hurdles that stand in the way of implementing a personalised approach to dosing in real world settings. In particular, our experience is illustrated by the application of a dosing platform for docetaxel treatment in prostate cancer.

1 Introduction

Drug development is a notoriously expensive and risky business. It is estimated that it costs around a billion dollars, from initial design to final patient trials, to develop a successful new treatment (1). The vast majority of new candidates of course do not get this far. And even if a drug does make it to market, the actual improvement that it offers over existing treatments may not be very great

Https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1154493/full?&utm_source=Email_to_authors_&utm_medium=Email&utm_content=T1_11.5e1_author